Cytomegalovirus gB Antibody (11B10D3E4) - Azide and BSA Free

Western Blot: Cytomegalovirus gB Antibody (11B10D3E4) [NBP3-06074] - Anti-Human cytomegalovirus (HCMV) Glycoprotein B gB mouse monoclonal antibody at 1:1000 Sample: Human cytomegalovirus (HCMV) Glycoprotein B gB Lane A: 100ng Lane B: 20ng Lane C: 4ng Secondary Rabbit Anti-Mouse IgGF ( ab ) 2 HRP at 1:1000 dilution. Performed under reducing conditions.

• Reactivity: V
• Applications: WB, ELISA
• Clone: 11B10D3E4
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: Azide and BSA Free

Cytomegalovirus gB Antibody (11B10D3E4) - Azide and BSA Free Summary

• Description: This antibody can be stored at 2C-8C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20C to -80C. Avoid repeated freeze-thaw cycles.
• Immunogen: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CMV gB (Accession#: AAA45920.1) extracellular domain (Met 1-Lys 700) linked with the cytoplasmic domain (Arg 777-Val 907).
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:1000-1:2000
  • Western Blot 1:1000-1:5000

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: 0.2 um filtered solution in PBS
• Preservative: No Preservative
• Purity: Protein A purified

Alternate Names for Cytomegalovirus gB Antibody (11B10D3E4) - Azide and BSA Free

• CMV glycoprotein B
• CMV glycoprotein GP55
• CMV
• Cytomegalovirus glycoprotein GP55
• gB
• Glycoprotein B
• Glycoprotein GP55
• HCMV glycoprotein B
• HCMV glycoprotein GP55
• HCMV
• HHV 5 glycoprotein B
• HHV 5 glycoprotein GP55
• HHV5 glycoprotein B
• HHV5 glycoprotein GP55
• Human herpesvirus 5 glycoprotein B
• Human herpesvirus 5 glycoprotein GP55
• UL55

Background

Human cytomegalovirus, also called HCMV or human herpesvirus 5, is a double-stranded DNA, enveloped virus of 230-250 kilobases (kb) that is a member of the Herpesviridae family and the subfamily Betaherpesvirinae (1,2). Other herpesviruses, which share the characteristic of lifelong latency following primary infection, include herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), varicella zoster virus (VSV), and Epstein-Barr virus (EBV) (1). Cytomegalovirus entry into cells is mediated by a trimeric complex of glycoproteins gH, gL, and gO and a pentamer made of proteins gH, gL, UL128, UL130, and UL131A (1,3). The trimer binds PDGFRalpha for entry into fibroblasts while the pentamer binds neuropilin-2 for entry into endothelial and epithelial cells (1,4). Additionally, the fusion protein glycoprotein B (gB) plays a pivotal role for cytomegalovirus entry into the host cell membrane (1,3).

Cytomegalovirus is a common virus, infecting ~60% of adults in developed countries and over 90% in developing countries, as indicated by presence of specific IgG antibodies (2-4). Although a majority of people infected remain asymptomatic, immunocompromised people, organ transplant recipients, and fetuses and newborns are more susceptible to HCMV-associated diseases (1-4). Annually, up to 2% of newborns are born with HCMV, making it the most common congenital infection (2-4). Cytomegalovirus is known to cause sensorineural hearing loss (SNHL), mental retardation, chorioretinitis, skin lesions, as well as end organ disease (3,5). There are a few CMV therapeutics approved by FDA including valganciclovir and letermovir; however, despite some benefits, there is the need for new antivirals and combination therapies (5). Potential new treatment options include monoclonal antibodies and sirtuins (5).

References

1. Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol. 2021;19(2):110-121. https://doi.org/10.1038/s41579-020-00448-w

2. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-773. https://doi.org/10.1038/s41579-021-00582-z

3. Krstanovic F, Britt WJ, Jonjic S, Brizic I. Cytomegalovirus Infection and Inflammation in Developing Brain. Viruses. 2021;13(6):1078. Published 2021 Jun 4. https://doi.org/10.3390/v13061078

4. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288-297. https://doi.org/10.1002/path.4437

5. Acosta E, Bowlin T, Brooks J, et al. Advances in the Development of Therapeutics for Cytomegalovirus Infections. J Infect Dis. 2020;221(Suppl 1):S32-S44. https://doi.org/10.1093/infdis/jiz493

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.